Referência de medicamentos
Enasidenib
Enasidenib is a medicine in the class oncology.
- Classe do medicamento: Oncology
Última atualização Fontes: US FDA label
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Pontos-chave
- Classe do medicamento
- Oncology
- Formas farmacêuticas comuns
- comprimido
- Interações conhecidas
- 5 (Grave: 1 · Moderada: 4)
- Nomes comerciais
- 1
- Países e mercados
- 1
Como funciona
Small molecule inhibitor of isocitrate dehydrogenase 2 (IDH2); targets mutant IDH2 variants R140Q, R172S and R172K, decreasing 2-hydroxyglutarate levels and inducing myeloid differentiation.
Dose habitual em adultos (resumo da bula)
Relapsed or refractory AML with IDH2 mutation: 100 mg orally once daily with or without food until disease progression or unacceptable toxicity; treat for a minimum of 6 months in patients without progression or unacceptable toxicity to allow clinical response
Gravidez e amamentação
- Gravidez
- Unsafe Can cause fetal harm: in rats and rabbits it caused embryo-fetal death and growth changes from 0.1 times human exposure; no human data. Verify pregnancy status. Use effective contraception during and for 2 months after; it can make hormonal pills less effective.
- Amamentação
- Unsafe No milk data. Because of possible adverse reactions in the infant, do not breastfeed during treatment and for 2 months after the last dose.
Efeitos adversos relatados
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Elevated bilirubin
- Differentiation syndrome
Advertências de caixa preta
- Differentiation syndrome can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.
Contraindicações
- None.
Quem deve ter cuidado
- Differentiation syndrome occurred in 14% of patients, as early as 1 day and up to 5 months after initiation; treat with corticosteroids (e.g., dexamethasone 10 mg every 12 hours) and hemodynamic monitoring; taper only after symptom resolution.
- Embryo-fetal toxicity: can cause fetal harm; verify pregnancy status before starting and use effective non-hormonal contraception during treatment and for 2 months after the last dose.
- Elevated bilirubin due to UGT1A1 inhibition; 37% of patients had total bilirubin ≥2 x ULN at least once.
Informe ao farmacêutico ou ao médico sobre gravidez ou amamentação, doença renal ou hepática, alergias e todos os outros medicamentos ou suplementos que você usa.
Principais interações (5)
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para abrir a monografia completa de Enasidenib: doses, gravidez e amamentação, efeitos adversos, advertências e todas as interações.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Experimente o Pro+ grátis por 7 dias na web. Sem cartão.
Outros medicamentos desta classe
Leituras rápidas relacionadas
Perguntas frequentes
What is Enasidenib used for?
Enasidenib is a medicine in the class oncology.
What side effects have been reported with Enasidenib?
Nausea, Diarrhea, Vomiting, Decreased appetite, Elevated bilirubin, Differentiation syndrome. Serious warning: Differentiation syndrome can be fatal if not treated.
Can Enasidenib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: in rats and rabbits it caused embryo-fetal death and growth changes from 0.1 times human exposure; no human data. Verify pregnancy status. Use effective contraception during and for 2 months after; it can make hormonal pills less effective. Breastfeeding: Unsafe. No milk data. Because of possible adverse reactions in the infant, do not breastfeed during treatment and for 2 months after the last dose.
What does Enasidenib interact with?
MediHelp lists 5 known interactions for Enasidenib. Major: 1 · Moderate: 4. The most serious include Rosuvastatin, Desogestrel-ethinyl estradiol, Ethinyl estradiol-levonorgestrel.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
